Takeda to evaluate Crescendo Biologics’ Humabodies
Crescendo Biologics has announced that Takeda is planning to evaluate the application of its recently licensed Humabodies, for the development of novel CAR-T therapeutics.
Read More
Tag: humabody
Takeda licenses Crescendo’s Humabodies
Japanese drug giant Takeda has taken an exclusive license to Cambridge, UK-based Crescendo Biologics’ Humabodies directed to one of its oncology targets.
Read More
UK’s Crescendo seals $790m Takeda deal
Takeda and Crescendo Biologics have signed a cancer drug development pact potentially worth nearly $800 million.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
